Author reply
Niklas Loman(Lund University), M�rten Fern�, Oskar T. Johannsson(Lapland Central Hospital), P�r-Ola Bendahl, �ke Borg
Cited by 0
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
|Cancer Cell|2017|534